- ￥108 - 439
- TargetMol
- USA
- T0373
- 2025年07月08日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
RT
- 保质期：
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -397℃ for several months.
- 英文名：
Erlotinib
- 库存：
详询
- 供应商：
详询
- CAS号：
183321-74-6
- 规格：
10mg/50mg/100mg/1ml/10mM
| 规格： | 10mg | 产品价格： | ￥108.0 |
|---|---|---|---|
| 规格： | 50mg | 产品价格： | ￥298.0 |
| 规格： | 100mg | 产品价格： | ￥439.0 |
| 规格： | 1ml/10mM | 产品价格： | ￥218.0 |
ID：T0373
PURITY：0.99
Formula：C22H23N3O4
MolWt：393.44
Appearance：白色粉末
Solubility：G4Soluble in water
Bioactivity：Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
Status：USP
Pathways：Tyrosine Kinase/Adaptors; JAK/STAT Signaling
Target：EGFR antagonist
Receptor：EGFR
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验肺癌是英国第二常见的癌症类型，每年有3.8万人被诊断出肺癌。针对表皮生长因子(EGF)受体的生物疗法被用于治疗EGF受体突变的肺癌患者。这些EGF受体抑制剂，包括阿法替尼、西妥昔单抗、吉非替尼和埃罗替尼，与化疗相比与改善无进展生存相关。然而，最终肿瘤会产生耐药性，这通常是由于EGF受体的进一步突变造成的。 在《BMC医学》发表的一项新研究中，Jacques De Greve和他的同事们探索了克服耐药性问题的新策略，并表明使用siRNA干扰EGF受体基因会导致肺癌细胞死亡。在orderChen
Oncolytic Viral Therapy Using Reovirus
Current mainstays in cancer treatment such as chemotherapy, radiation therapy, hormonal manipulation, and even targeted therapies such as trastuzumab (Herceptin) for breast cancer or erlotinib (Tarceva) for non-small cell lung cancer
strategies. EGFR mutation profiling assesses gefitinib or erlotinib efficacy in non-small cell lung cancer patients. Tumor genotyping of multiple genes and/or mutations, however, is not widely deployed due to the high cost of analyzing these regions
技术资料暂无技术资料 索取技术资料
